Novartis sales held steady despite new Gleevec generics, and the Swiss drugmaker is optimistic enough about new meds to sink more money into marketing and…

Amid a period of intense drug pricing scrutiny, data are out on the costliest drugs to Medicaid, with some of pharma's biggest names among the highest-…

When Pfizer CEO Ian Read raised the idea of a big split, it was catnip for investors. But one top analyst now believes Read won't take the plunge.

Drugs companies continue to raise their prices.

Worldwide, less than half of Type 2 diabetes patients are taking their medicines in an "optimal" manner, according to a new report, leaving plenty of…

The European Medicines Agency, the drug regulator for Europe, is headquartered in London. The problem is that the U.K. voted Thursday to leave the European…

These days, top drugmakers don’t start their own seeds. They transplant seedlings instead. But according to an EP Vantage report, some companies are more…

Blockbuster drug launches have strained health systems budgets in recent years by driving sizable spending hikes. But that trend may be nearing a lull, a new…

Pharma may have pulled off only a few outcomes-based pricing deals with payers, but companies are likely to add more to that list soon--many more, if payers…